HUMANA INC — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Humana reported 2Q26 adjusted EPS of $7.61 and YTD adjusted EPS of $17.91, affirming full-year 2026 adjusted EPS guidance of 'at least $9.00'. However, the company revised GAAP EPS guidance downward to 'at least $6.52' from 'at least $8.36', primarily due to a Medicare Star Ratings headwind for 2026. Individual Medicare Advantage membership grew ~23% YTD (tracking to ~25% FY guidance); CenterWell Primary Care added 130,900 patients YTD (+27%); and Humana won a statewide Illinois Medicaid contract effective January 2027.
Why this rating
Modest near-term headwind (Star Ratings cut to GAAP outlook) offset by solid operational execution and strategic wins. Relative to $29.2B market cap, membership growth and CenterWell expansion are meaningful but not transformational; GAAP guidance cut of $1.84/share (~2% of cap) is material but disclosed in advance.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.